




## Orphenadrine

Revised: November 16, 2020.

CASRN: 83-98-7



## Drug Levels and Effects

### Summary of Use during Lactation

No published information is available on the use of orphenadrine during breastfeeding. Manufacturer's estimates indicate that the amount in milk may be low. The drug's anticholinergic activity might interfere with milk production. An alternate agent may be preferred.

### Drug Levels

*Maternal Levels.* A European manufacturer of orphenadrine estimated that with a maternal dose of 150 mg, milk orphenadrine concentration would be about 300 to 400 mcg/L.[1] This implies that the relative infant dosage might be about 1.8 to 2.4% of the mother's weight-adjusted dosage.

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

**Attribution Statement:** LactMed is a registered trademark of the U.S. Department of Health and Human Services.

*Infant Levels.* Relevant published information was not found as of the revision date.

## Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

## Effects on Lactation and Breastmilk

Orphenadrine has anticholinergic activity. Anticholinergics can inhibit lactation in animals, apparently by inhibiting growth hormone and oxytocin secretion.[2-6] Anticholinergic drugs can also reduce serum prolactin in nonnursing women.[7] The prolactin level in a mother with established lactation may not affect her ability to breastfeed.

## References

1. Chaplin S, Sanders GL, Smith JM. Drug excretion in human breast milk. *Adv Drug React Ac Pois Rev.* 1982;1:255–87.
2. Aaron DK, Ely DG, Deweese WP, et al. Reducing milk production in ewes at weaning using restricted feeding and methscopolamine bromide. *J Anim Sci.* 1997;75:1434–42. PubMed PMID: 9250502.
3. Powell MR, Keisler DH. A potential strategy for decreasing milk production in the ewe at weaning using a growth hormone release blocker. *J Anim Sci.* 1995;73:1901–5. PubMed PMID: 7592071.
4. Daniel JA, Thomas MG, Powell MR, et al. Methscopolamine bromide blocks hypothalamic-stimulated release of growth hormone in ewes. *J Anim Sci.* 1997;75:1359–62. PubMed PMID: 9159285.
5. Bizzarro A, Iannucci F, Tolino A, et al. Inhibiting effect of atropine on prolactin blood levels after stimulation with TRH. *Clin Exp Obstet Gynecol.* 1980;7:108–11. PubMed PMID: 6788407.
6. Svennersten K, Nelson L, Juvnas-Moberg K. Atropinization decreases oxytocin secretion in dairy cows. *Acta Physiol Scand.* 1992;145:193–4. PubMed PMID: 1636447.
7. Masala A, Alagna S, Devilla L, et al. Muscarinic receptor blockade by pirenzepine: Effect on prolactin secretion in man. *J Endocrinol Invest.* 1982;5:53–5. PubMed PMID: 6808052.

## Substance Identification

### Substance Name

Orphenadrine

### CAS Registry Number

83-98-7

### Drug Class

Breast Feeding

Lactation

Antiparkinson Agents

Cholinergic Antagonists

Muscle Relaxants, Central

Parasympatholytics

Muscarinic Antagonists